Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovoCureFRA:038 +3.24%70 Forward PE Ratio is 0.00 as of Aug. 05, 2026. GuruFocus rates FRA:038 with a GF Score™ of 70/100 and a GF Value™ of €15.08 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 391 Medical Devices & Instruments companies, NovoCure ranks worse than 255754.22% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
NovoCure Forward PE Ratio Related Terms
NovoCure Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for NovoCure's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure Forward PE Ratio Chart
NovoCure Annual Data
Trend
2019-12
2020-12
2021-12
Forward PE Ratio
85.47
322.58
588.24
NovoCure Quarterly Data
2018-09
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-09
2021-12
Forward PE Ratio
156.25
909.09
68.49
85.47
81.97
90.91
263.16
322.58
5,000.00
909.09
588.24
FRA:038 vs NEOG, AXGN, UFPT: Forward PE Ratio Comparison
For the Medical Devices subindustry, NovoCure's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where NovoCure's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
NovoCure (FRA:038) has a Forward PE Ratio of 0.00 as of Aug. 05, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on NovoCure and its competitors. According to the industry distribution chart, NovoCure ranks #999999 out of 391 companies in the Medical Devices & Instruments industry.
Is NovoCure's Forward PE Ratio too high?
NovoCure's current Forward PE Ratio is 0.00. Based on the distribution chart, NovoCure ranks #999999 out of 391 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NovoCure has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Forward PE Ratio compare to NEOG and AXGN?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #999999 out of 391 companies for Forward PE Ratio. This places NovoCure in the lower half of its industry. The industry median Forward PE Ratio is 19.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.79, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on NovoCure and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovoCure's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (FRA:038) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.08, compared to a current price of €13.05 — trading 13.5% below its estimated fair value. The current Forward PE Ratio is 0.00. NovoCure's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For NovoCure (FRA:038), the current Forward PE Ratio is 0.00 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (FRA:038) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of €13.05 is trading 13.5% below its estimated GF Value™ of €15.08.
GuruFocus considers NovoCure to be Modestly Undervalued.
Key valuation signals for FRA:038:
Forward PE Ratio: 0.00
GF Value™: €15.08 vs. price of €13.05 (13.5% below fair value)
No single metric tells the full story. See the FRA:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
70GF Score
Get the complete analysis for FRA:038
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:038 has been successfully added to your 
